Oleg Gluz, ESMO 2022: Analysis of ADAPT and ADAPTcycle trials – Endocrine therapy response in breast cancer
The benefit of chemotherapy addition to endocrine therapy remains controversial in premenopausal patients. In this touchONCOLOGY interview Dr Oleg Gluz (West German Study Group, Mönchengladbach, Germany) discusses the ongoing phase III ADAPT cycle trial investigating the impact of age, recurrence score, and ovarian function suppression on endocrine therapy response.
The abstract entitled ‘Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials‘ Abstract LBA14, was presented at European Society for Medical Oncology (ESMO) 2022.
Questions:
- What controversy persists around the addition of chemotherapy to endocrine therapy in premenopausal women with breast cancer? (0:26)
- Could you tell us a little about the ADAPT and ADAPTcycle clinical trials? (3:05)
- What were the aims and design of the current analysis? (5:09)
- What were the findings of the analysis? (7:50)
Disclosures: Oleg Gluz is on the advisory board for Roche, Lilly, Amgen, Novartis, Pierre Fabre, MSD, Celgene, Pfizer, Gilead, Molecular Health, Seagen; and has financial interests, and is an invited speaker for AstraZeneca, Exact Science, and Roche.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
